DFCI 21-159 ATEMPT 2.0

A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)

Objective

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combinations of HER2-directed therapies as a treatment after surgery.

NCT#04893109

Clinical Trial Categories

• Breast Cancer

Contact

NH Oncology Hematology Clinical Research Dept. at (603) 224-2556